Literature DB >> 23800180

N-terminal pro-brain natriuretic peptide level determined at different times identifies transient ischaemic attack patients with atrial fibrillation.

F Purroy1, I Suárez-Luis, G Mauri-Capdevila, S Cambray, J Farré, J Sanahuja, G Piñol-Ripoll, A Quílez, C González-Mingot, R Begué, M I Gil, E Fernández, I Benabdelhak.   

Abstract

BACKGROUND AND
PURPOSE: The etiological classification of patients with transient ischaemic attack (TIA) is a difficult endeavor and the use of serum biomarkers could improve the diagnostic accuracy. The aim of this study was to correlate atrial fibrillation, the main cardioembolic etiology (CE), with different serum biomarkers measured in consecutive TIA patients.
METHODS: The concentrations of interleukin-6 (IL-6), tumor necrosis factor-alpha, neuron-specific enolase, high-sensitivity C-reactive protein, IL-1-α and the N-terminal pro-B type natriuretic peptide (NT-proBNP) were quantified in the serum of 140 patients with TIA and 44 non-stroke subjects. Measurements were performed at different times throughout evolution: within 24 h of symptoms onset and at days 7 and 90.
RESULTS: With the exception of IL-6, all biomarkers were higher in TIA patients than in controls. NT-proBNP was significantly related to the presence or new diagnosis of AF at all time points analyzed. Furthermore, the baseline NT-proBNP level was significantly higher than values at the 7-day and 90-day follow-up. For this reason, different cut-off values were obtained at different times: 313 pg/ml at baseline [odds ratio (OR) = 18.99, P < 0.001], 181 pg/ml at 7 days (OR = 11.4, P = 0.001) and 174 pg/ml (OR = 8.46, P < 0.001) at 90 days.
CONCLUSION: High levels of NT-proBNP determined during the first 3 months after a TIA were associated with AF. Consequently, this biomarker may be useful to reclassify undetermined TIA patients as having disease of CE.
© 2013 The Author(s) European Journal of Neurology © 2013 EFNS.

Entities:  

Keywords:  NT-proBNP; atrial fibrillation; biomarker; cardioembolic; transient ischemic attack

Mesh:

Substances:

Year:  2013        PMID: 23800180     DOI: 10.1111/ene.12222

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  5 in total

1.  Metabolomics predicts stroke recurrence after transient ischemic attack.

Authors:  Mariona Jové; Gerard Mauri-Capdevila; Idalmis Suárez; Serafi Cambray; Jordi Sanahuja; Alejandro Quílez; Joan Farré; Ikram Benabdelhak; Reinald Pamplona; Manuel Portero-Otín; Francisco Purroy
Journal:  Neurology       Date:  2014-12-03       Impact factor: 9.910

2.  European Stroke Organisation (ESO) guideline on screening for subclinical atrial fibrillation after stroke or transient ischaemic attack of undetermined origin.

Authors:  Marta Rubiera; Ana Aires; Kateryna Antonenko; Sabrina Lémeret; Christian H Nolte; Jukka Putaala; Renate B Schnabel; Anil M Tuladhar; David J Werring; Dena Zeraatkar; Maurizio Paciaroni
Journal:  Eur Stroke J       Date:  2022-06-03

Review 3.  Promising Biomarker Candidates for Cardioembolic Stroke Etiology. A Brief Narrative Review and Current Opinion.

Authors:  Arnold Markus; Schütz Valerie; Katan Mira
Journal:  Front Neurol       Date:  2021-02-25       Impact factor: 4.003

4.  Risk of New-Diagnosed Atrial Fibrillation After Transient Ischemic Attack.

Authors:  Francisco Purroy; Mikel Vicente-Pascual; Gloria Arque; Robert Begue; Joan Farre; Yhovany Gallego; Maria Pilar Gil-Villar; Gerard Mauri; Nuria Montalà; Cristina Pereira; Coral Torres-Querol; Daniel Vazquez-Justes
Journal:  Front Neurol       Date:  2022-07-14       Impact factor: 4.086

5.  Inflammatory Response of Ischemic Tolerance in Circulating Plasma: Preconditioning-Induced by Transient Ischemic Attack (TIA) Phenomena in Acute Ischemia Patients (AIS).

Authors:  Laura Colàs-Campàs; Joan Farre; Gerard Mauri-Capdevila; Jessica Molina-Seguín; Núria Aymerich; Ángel Ois; Jaume Roquer; Silvia Tur; María Del Carmen García-Carreira; Joan Martí-Fàbregas; Antonio Cruz-Culebras; Tomás Segura; Gloria Arque; Francisco Purroy
Journal:  Front Neurol       Date:  2020-10-29       Impact factor: 4.003

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.